Lineage Cell Therapeutics, Inc.

LCTX NYSE CIK: 0000876343

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation CA
Business Address 2173 SALK AVENUE, CARLSBAD, CA, 92008
Mailing Address 2173 SALK AVENUE, CARLSBAD, CA, 92008
Phone 5105213390
Fiscal Year End 1231
EIN 943127919

Financial Overview

FY2025

$69.24M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 12, 2026 View on SEC
8-K Current report of material events March 11, 2026 View on SEC
424B5 Prospectus supplement March 11, 2026 View on SEC
S-3 Shelf registration for future offerings March 11, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
10-K Annual financial report March 5, 2026 View on SEC
8-K Current report of material events March 5, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC

Annual Reports

10-K March 5, 2026
  • Advancing innovative cell therapies with lead programs OpRegen®, VAC2™, and OLMAI™.
  • Reported $80.3 million in cash and cash equivalents as of December 31, 2025, projected to fund operations into late 2026.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.